ATE387460T1 - Verfahren und kit zur beurteilung des ausbruchs von rheumatoider arthritis - Google Patents

Verfahren und kit zur beurteilung des ausbruchs von rheumatoider arthritis

Info

Publication number
ATE387460T1
ATE387460T1 AT03700501T AT03700501T ATE387460T1 AT E387460 T1 ATE387460 T1 AT E387460T1 AT 03700501 T AT03700501 T AT 03700501T AT 03700501 T AT03700501 T AT 03700501T AT E387460 T1 ATE387460 T1 AT E387460T1
Authority
AT
Austria
Prior art keywords
rheumatoid arthritis
protein
kit
outbreak
assessing
Prior art date
Application number
AT03700501T
Other languages
English (en)
Inventor
Shunichi Shiozawa
Koichiro Komai
Mikiko Nakatsukasa
Original Assignee
Shunichi Shiozawa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shunichi Shiozawa filed Critical Shunichi Shiozawa
Application granted granted Critical
Publication of ATE387460T1 publication Critical patent/ATE387460T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/10Musculoskeletal or connective tissue disorders
    • G01N2800/101Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/102Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • Rheumatology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Pathology (AREA)
  • Rehabilitation Therapy (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Physics & Mathematics (AREA)
  • Diabetes (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
AT03700501T 2002-01-11 2003-01-08 Verfahren und kit zur beurteilung des ausbruchs von rheumatoider arthritis ATE387460T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2002005326A JP4242590B2 (ja) 2002-01-11 2002-01-11 慢性関節リウマチの疾患感受性遺伝子、及びその利用

Publications (1)

Publication Number Publication Date
ATE387460T1 true ATE387460T1 (de) 2008-03-15

Family

ID=19191091

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03700501T ATE387460T1 (de) 2002-01-11 2003-01-08 Verfahren und kit zur beurteilung des ausbruchs von rheumatoider arthritis

Country Status (11)

Country Link
US (1) US7615341B2 (de)
EP (1) EP1471143B1 (de)
JP (1) JP4242590B2 (de)
KR (1) KR100976005B1 (de)
AT (1) ATE387460T1 (de)
CA (1) CA2473218C (de)
DE (1) DE60319342T2 (de)
DK (1) DK1471143T3 (de)
ES (1) ES2301778T3 (de)
PT (1) PT1471143E (de)
WO (1) WO2003060126A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4657757B2 (ja) * 2005-02-23 2011-03-23 株式会社膠原病研究所 肺高血圧症発症関連遺伝子を用いた肺高血圧症の診断および治療
JP2006325528A (ja) * 2005-05-27 2006-12-07 Institute For Rheumatic Diseases Co Ltd 糖尿病性網膜症の診断および予防
JP4657857B2 (ja) * 2005-08-25 2011-03-23 株式会社膠原病研究所 メタボリックシンドロームの診断および予防
JP2009136229A (ja) * 2007-12-07 2009-06-25 Institute For Rheumatic Diseases Co Ltd 自己免疫疾患モデル細胞又は自己免疫疾患モデル動物の作製方法、並びに自己免疫疾患の診断方法
EP3314018A1 (de) * 2015-06-24 2018-05-02 Oxford Biodynamics Limited Nachweisverfahren unter verwendung von chromosominteraktionsstellen

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5585464A (en) 1993-02-19 1996-12-17 Theratech, Inc. Recombinant antigen for diagnosing rheumatoid arthritis
US5814464A (en) * 1994-10-07 1998-09-29 Regeneron Pharma Nucleic acids encoding TIE-2 ligand-2
EP0821728B1 (de) 1995-04-06 2004-08-11 Regeneron Pharmaceuticals, Inc. Tie-2 liganden, herstellungsverfahren und verwendung
KR20010012591A (ko) 1997-05-15 2001-02-15 시오자와 순이찌 만성관절 류우머티스의 질환유전자, 만성관절류우머티스의 진단방법 및 만성관절 류우머티스원인인자의 결정방법
EP1098665B9 (de) 1998-07-13 2003-08-13 The Board Of Regents, The University Of Texas System Krebsbehandlung mit aminophospholipide bindenden, therapeutischen konjugaten
AU5472899A (en) * 1998-08-20 2000-03-14 Incyte Pharmaceuticals, Inc. Human angiopoietin-3
KR100755504B1 (ko) * 1999-03-20 2007-09-04 시오자와 순이찌 만성 류마티스성 관절염질환 유전자
ES2223705T3 (es) * 1999-04-28 2005-03-01 Board Of Regents, The University Of Texas System Composiciones y metodos para el tratamiento de cancer mediante inhibi cion selectiva del vegf.
DE10100586C1 (de) * 2001-01-09 2002-04-11 Ribopharma Ag Verfahren zur Hemmung der Expression eines Ziegens
JP3596433B2 (ja) * 2000-06-29 2004-12-02 株式会社デンソー 車載用電子制御装置
US7306908B2 (en) 2000-10-24 2007-12-11 Shunichi Shiozawa Nucleic acids associated with rheumatoid arthritis, and methods and kits for the diagnosis thereof

Also Published As

Publication number Publication date
KR20040077715A (ko) 2004-09-06
DE60319342D1 (de) 2008-04-10
ES2301778T3 (es) 2008-07-01
US7615341B2 (en) 2009-11-10
EP1471143A4 (de) 2005-09-14
JP4242590B2 (ja) 2009-03-25
KR100976005B1 (ko) 2010-08-17
US20050176004A1 (en) 2005-08-11
CA2473218C (en) 2011-07-19
WO2003060126A1 (en) 2003-07-24
CA2473218A1 (en) 2003-07-24
DE60319342T2 (de) 2009-03-19
JP2003204790A (ja) 2003-07-22
DK1471143T3 (da) 2008-06-16
AU2003201847A1 (en) 2003-07-30
EP1471143B1 (de) 2008-02-27
EP1471143A1 (de) 2004-10-27
PT1471143E (pt) 2008-05-20

Similar Documents

Publication Publication Date Title
ATE353974T1 (de) Verfahren, zusammensetzungen und kits zur identifizierung und überwachung von brustkrebs
ATE420204T1 (de) Verfahren zur detektion von erkrankungen
DE60140773D1 (de) Polypeptide zur Bindung an das B-Lymphozyten-stimulatorische Protein (BLyS)
ATE354638T1 (de) Menschlicher gewebsinhibitor von metalloproteinase-4
ATE548388T1 (de) An den interleukin-4-rezeptor bindende antikörper
IL154794A0 (en) Remedies for heart failure
ATE415175T1 (de) Ace2-aktivierung zur behandlung von herz, lungen, und nierenkrankheit und bluthochdruck
WO2002059604A3 (en) Diagnosis and treatment of multiple sclerosis
ATE435657T1 (de) Therapeutische zubereitung von hochreinem fviia und verfahren zu dessen gewinnung
DK0750672T3 (da) DNA-sekvenser for matrix-metalproteaser, deres tilvejebringelse og anvendelse
ATE168135T1 (de) Diagnose von retinoblastoma
ATE387460T1 (de) Verfahren und kit zur beurteilung des ausbruchs von rheumatoider arthritis
EP0876491A4 (de) Ein gen des "langen qt syndroms" (long qt syndrom), welches kvlqt1 kodiert und seine wechselwirkung mit mink
DK1373502T3 (da) Dopaminerge neuronale overlevelsesfremmende faktorer og avendelser heraf
DE69204157D1 (de) Verfahren zur bestimmung von anti-rns-antikörpern.
ATE534902T1 (de) Replikationsproteinn ciz1
EP1575993A4 (de) Verfahren zur behandlung von patienten und zur identifizierung von therapeutika
PT1379650E (pt) Segmentos preferidos da proteina de cadeia neuronal ntp e procedimentos para a sua utilizacao.
ATE490979T1 (de) Neueskollagen-ähnliches protein clac, dessen vorläufer und dafür kodierende gene
WO2008037720A3 (en) Means and methods for diagnosing and/or treating a subject at risk of developing heart failure
DE50303798D1 (de) Vorrichtung, um in einem Zielgebiet eines menschlichen oder tierischen Körpers einen künstlichen isolierten Kreislauf zu etablieren
ATE312914T1 (de) Rdgb-proteine
EE200000478A (et) Peptiid, seda kodeeriv geen, diagnostiline reagent ja diagnostiline reaktiivikomplekt ning vaktsiinkasutamiseks riketsioosi ravis
DE502004012230D1 (de) Verfahren zur diagnose von erkrankungen unter bestimmung von apolipoprotein c-i
ATE407944T1 (de) Mit trp-proteinen verwandtes protein mtr1 und dieses codierende dna-sequenz

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1471143

Country of ref document: EP